Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target
Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $155 price target.
Stocks · News reference
Nurix Gets $10M As Gilead Extends Drug Discovery Deal
Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Nurix and
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $158
Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $150 to $158.
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $170
JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $160 to $170.
Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $163
Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $165 to $163.
Stock Market: Will S&P 500 Open Up or Down Today?
Will S&P 500 open higher? Polymarket odds sit at 52% as Wall Street weighs 5.35% Treasury yields, potential Iran strikes, and Pepsi earnings.
Nurix Therapeutics Enrolls First Patient In Phase 1b/2 Study Of Bexobrutideg Plus Venetoclax In Chronic Lymphocytic Leukemia Under Roche Collaboration
First patient enrolled in cohort combining bexobrutideg with venetoclaxInitial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLLStrategy includes evaluation of bexobrutideg given in